Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis.
The objective of this study was to evaluate the safety and efficacy of allogeneic bone marrow mesenchymal stromal/stem cell transplantation (BM-MSCT) for patients with ursodeoxycholic acid (UDCA)-resistant primary biliary cirrhosis (PBC). Ten patients were enrolled in this trial of BM-MSCT. All patients were permitted to concurrently continue their previous UDCA treatment. The efficacy of BM-MSCT in UDCA-resistant PBC was assessed at various time points throughout the 12-month follow up. No transplantation-related side effects were observed. The life quality of the patients was improved after BM-MSCT as demonstrated by responses to the PBC-40 questionnaire. Serum levels of ALT, AST, γ-GT, and IgM significantly decreased from baseline after BM-MSCT. In addition, the percentage of CD8+ T cells was reduced, while that of CD4+CD25+Foxp3+ T cells was increased in peripheral lymphocytic subsets. Serum levels of IL-10 were also elevated. Notably, the optimal therapeutic outcome was acquired in 3 to 6 months and could be maintained for 12 months after BM-MSCT. In conclusion, allogeneic BM-MSCT in UDCA-resistant PBC is safe and appears to be effective.
1 Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH) , Chinese Academy of Medical Science, Beijing, China .
Li
L
Wang
Qin
Q
Han
Hua
H
Chen
Ke
K
Wang
Guang-liang
GL
Shan
Fang
F
Kong
Yun-jiao
YJ
Yang
Yong-zhe
YZ
Li
Xuan
X
Zhang
Fen
F
Dong
Qian
Q
Wang
Dong
D
Xu
Zhao-jun
ZJ
Hu
Shi-hua
SH
Wang
Armand
A
Keating
Ya-lan
YL
Bi
Feng-chun
FC
Zhang
Robert Chun-hua
RC
Zhao
D000328:Adult; D016026:Bone Marrow Transplantation; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000628:therapy*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*
D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid